Drug Profile
JP 9303
Latest Information Update: 22 May 2001
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class Antibacterials
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 22 May 2001 Profile reviewed but no significant changes made
- 14 Jul 1998 No-Development-Reported for Bacterial infections in South Korea (Unknown route)
- 23 Jun 1995 Phase-II clinical trials for Bacterial infections in South Korea (Unknown route)